1.A Case of Phenytoin Induced Toxic Epidermal Necrolysis.
Hae Joung JOUNG ; Wea Kyoun SHIN ; Mee Kyung NAMKUNG ; Jae Seung YANG ; Jong Soo KIM ; Dong Sik BANG
Journal of the Korean Pediatric Society 1990;33(9):1306-1311
No abstract available.
Phenytoin*
;
Stevens-Johnson Syndrome*
2.The Current Trend in the Diagnosis and Management of Ectopic Pregnancy.
Beom Seok CHOI ; Hae Mee BANG ; Jang Chul CHO ; Tae Sil KIM ; Kwan Sik KIM ; Jong Duk KIM
Korean Journal of Obstetrics and Gynecology 1997;40(11):2421-2429
This retrospective study was undertaken to investigate the current clinical trend in the management of ectopic pregnancy. 562 patients of ectopic pregnancy were admitted and managed at the Department of Obstetrics and Gynecology, Chonbuk National University Hospital from Jan. 1. 1985 to Dec. 31. 1996. All cases had a reliable medical record and were divided into two groups, of which group A includes patients admitted from Jan. 1. 1985 to Dec. 31. 1990, group B from the Jan. 1. 1991 to Dec. 31. 1996. The results were obtained as follows. 1. The number of cases of ectopic pregnancy were 248 in group A and 314 in group B. 2. The age group of 20 to 29 years of age was top ranked in group A(49.6%) as well as in group B(46.8%). The age group of 30 to 39 years was 43.2% in group A and 46.6% in group B, respectively. 3. In group A, the case who experienced two deliveries was 31.9%, and nulliparous woman was 30.6%. In group B, the case who experienced two deliveries was 33.1%, nulliparous woman was 33.1%. 4. On reviewing the past medical history, ectopic pregnancy was 11.2% in group A, 10.8% in group B, respectively. Pelvic inflammatory disease was 8.1% in group A and 11.0% in group B, respectively. 5. The interval between the last menstrual period and the onset of symptoms was prevalently in 4 to 8 weeks(64.5% in group A, 61.8% in group B). The terval of 12 weeks or more was 2.0% in group A and 6.0% in group B, respectively. 6. In considering the chief complaints, low abdominal pain was 85.9% and vaginal spotting was 69.0% in group A. On the other hand, low abdominal pain was 91.4% and vaginal spotting was 76.4% in group B, meanwhile nausea and vomitting was 8.6% and dizziness was 3.5% in group A, there were 23.4% of nausea and vomitting and 9.7% of dizziness in group B,7. In relation of the diagnostic methods, the positive rate of culdocentesis in group B was lower than the rate in group A. Diagnostic laparoscopy was done in 5.6% of group A and 14% of group B. The detection rate of adnexal mass and fluid collection in the pelvic cavity was higher in group B than in group A on the ultrasonographic examination. 8. Initial hemoglobin value of 10.1mg/dl or more was 70.9% in group A and 73.2% in group B. The value of 8.0gm/dl or less was 6.4% in group A and 7.0% of group B, respectively. Initial systolic pressure of 110mmHg or more was 74.6% in group A and 66.6% in group B. The systolic pressure of 90mmHg or less was 3.6% in group A and 8.3% in group B.9. The conceptus was almost implantd in the fallopian tube. The ampullary portion was the most common site of ectopic implantation in both groups. 10. Intraabdominal hemorrhage of 500ml or less in amount was 52.4% in group A and 61.1% in group B, individually. However transfusion was not given in 55.6% of group A and in 71.0% of group B. 11. In the therapeutic modalities, laparotomy was performed in 96.8% of group A and in 82.8% of group B, respectively. The pelviscopic operation was done in 2.4% of group A and in 22.3% of group B. In conclusion, ectopic pregnancy was diagnosed increasingly prior to the onset of the hypovolemic symptoms according to developement of high-resolution ultrasonogram, diagnostic laparoscopy and beta-hCG test, therefore the use of minimally invasive techniques in the management of ectopic pregnancy was increasing.
Abdominal Pain
;
Blood Pressure
;
Diagnosis*
;
Dizziness
;
Fallopian Tubes
;
Female
;
Gynecology
;
Hand
;
Hemorrhage
;
Humans
;
Hypovolemia
;
Jeollabuk-do
;
Laparoscopy
;
Laparotomy
;
Medical Records
;
Metrorrhagia
;
Nausea
;
Obstetrics
;
Pelvic Inflammatory Disease
;
Pregnancy
;
Pregnancy, Ectopic*
;
Retrospective Studies
;
Ultrasonography
3.Antiemetic Effect of Granisetron plus Dexamethasone for the Patients Refractory to Metoclopramide , Dexamethasone and Lorazepam ( MDL ).
Se Hoon LEE ; Dong Wan KIM ; Kyun Hae JUNG ; Soo Mee BANG ; Jae Ho BYUN ; Heung Moon CHANG ; Dae Seog HEO ; Yung Jue BANG ; Noe Kyeong KIM
Journal of the Korean Cancer Association 1999;31(5):1027-1034
PURPOSE: The combination of dexamethasone and granisetron provides effective prophylaxis in patients treated with high-dose cisplatin. We performed this study to evaluate the antiemetic effect of granisetron plus dexamethasone for the patients refractory to metoclo- pramide, dexamethasone, lorazepam (MDL) regimen. MATERIALS AND METHODS: From 1996 to 1998, we administered the MDL regimen in patients who received high-dose cisplatin (more than 60 mg/m/day) for the first time. The granisetron plus dexamethasone were administered in the subsequent cycle for the patients refractory to the MDL regimen during the first or the second cycle of chemotherapy. Efficacies of treatment were assessed daily from days 1 to 5. Complete response was defined as the absence of vomiting episodes and major response as 1 or 2 episodes per day. Complete or major responses were considered effective. RESULTS: Twenty patients received granisetron plus dexamethasone therapy. During the first 24 hours, complete and major responses were achieved in 75% and 15% respectively, thus it was effective in 90% of patients. For delayed vomiting (occurring during days 2 through 5), complete and major responses were achieved in 30% and 50% respectively, thus it was effective in 80%. Side effects included hiccups, headache, diarrhea, sedation, dizziness and insomnia, but discontinuation or dose adjustment was not needed. CONCLUSION: The granisetron plus dexamethasone regimen was an effective antiemetic regimen for the patients refractory to the MDL regimen.
Antiemetics*
;
Cisplatin
;
Dexamethasone*
;
Diarrhea
;
Dizziness
;
Drug Therapy
;
Granisetron*
;
Headache
;
Hiccup
;
Humans
;
Lorazepam*
;
Metoclopramide*
;
Sleep Initiation and Maintenance Disorders
;
Vomiting
4.Development of Gender-Sensitive Comprehensive Health Matrix: A Comparative Study on the Cases of Sustainable Development Goals Countries and North Korea Based on Gender-Sensitive Indicators
Yoorim BANG ; Youngrin KWAG ; Eun Mee KIM ; Eunhee HA ; Oran KWON ; Hae Soon KIM ; Hyesook KIM ; Seok Hyang KIM ; Miju KIM ; Eunshil KIM ; Jae Jin HAN ; Kooyoung JUNG ; Hunjoo HA
Journal of the Korean Society of Maternal and Child Health 2020;24(1):40-51
Purpose:
South Korea ranked 18th out of the 162 participating countries in the 2019 report on sustainable development goals (SDGs). Among the 17 specified goals, it has the most difficulty in achieving gender equality (SDG 5). This shortcoming is manifested in the lack of studies on gender-sensitive indicators. The study aims to establish the significance of the development of a comprehensive health matrix to concretize the concept of gender-sensitivity which is often considered as abstract.
Methods:
An integrated analysis of health determinants was conducted through a convergence study involving medical, social and natural sciences. This analysis was based on both literature reviews and focusgroup discussions. The 6 following focal points were chosen based on the SDGs: gender equality, medicine, education, economy, nutrition, and environment. Objective quantitative indicators were then designated to each of the 6 areas and comparatively analyzed for South Korea, North Korea, and the other SDGs countries. Four areas on sexual and reproductive health were also selected.
Results:
The results indicated that South Korea scored much lower than North Korea and the other SDGs countries in terms of gender equality. It was also behind North Korea in education, although North Korea had a comparatively lower ranking in the rest of the areas. On the other hand, it fared better than the aforementioned countries with respect to environment, nutrition, medicine, and economy.
Conclusion
A comprehensive gender-sensitive health matrix was developed to refine the abstract concept of gender-sensitivity through objective quantitative indicators that assess the health status of a country by means of a scoring system. Gender equality was also confirmed as a common and significant component in the disciplines of sexual and reproductive health and comprehensive health.
5.Development of Gender-Sensitive Comprehensive Health Matrix: A Comparative Study on the Cases of Sustainable Development Goals Countries and North Korea Based on Gender-Sensitive Indicators
Yoorim BANG ; Youngrin KWAG ; Eun Mee KIM ; Eunhee HA ; Oran KWON ; Hae Soon KIM ; Hyesook KIM ; Seok Hyang KIM ; Miju KIM ; Eunshil KIM ; Jae Jin HAN ; Kooyoung JUNG ; Hunjoo HA
Journal of the Korean Society of Maternal and Child Health 2020;24(1):40-51
Purpose:
South Korea ranked 18th out of the 162 participating countries in the 2019 report on sustainable development goals (SDGs). Among the 17 specified goals, it has the most difficulty in achieving gender equality (SDG 5). This shortcoming is manifested in the lack of studies on gender-sensitive indicators. The study aims to establish the significance of the development of a comprehensive health matrix to concretize the concept of gender-sensitivity which is often considered as abstract.
Methods:
An integrated analysis of health determinants was conducted through a convergence study involving medical, social and natural sciences. This analysis was based on both literature reviews and focusgroup discussions. The 6 following focal points were chosen based on the SDGs: gender equality, medicine, education, economy, nutrition, and environment. Objective quantitative indicators were then designated to each of the 6 areas and comparatively analyzed for South Korea, North Korea, and the other SDGs countries. Four areas on sexual and reproductive health were also selected.
Results:
The results indicated that South Korea scored much lower than North Korea and the other SDGs countries in terms of gender equality. It was also behind North Korea in education, although North Korea had a comparatively lower ranking in the rest of the areas. On the other hand, it fared better than the aforementioned countries with respect to environment, nutrition, medicine, and economy.
Conclusion
A comprehensive gender-sensitive health matrix was developed to refine the abstract concept of gender-sensitivity through objective quantitative indicators that assess the health status of a country by means of a scoring system. Gender equality was also confirmed as a common and significant component in the disciplines of sexual and reproductive health and comprehensive health.
6.Coinfection of hepatitis A virus genotype IA and IIIA complicated with autoimmune hemolytic anemia, prolonged cholestasis, and false-positive immunoglobulin M anti-hepatitis E virus: a case report.
Hee Sup KIM ; Sook Hyang JEONG ; Je Hyuck JANG ; Hyung Joon MYUNG ; Jin Wook KIM ; Soo Mee BANG ; Sang Hoon SONG ; Haeryoung KIM ; Hae Sun YUN
The Korean Journal of Hepatology 2011;17(4):323-327
A 37-year-old male presented with fever and jaundice was diagnosed as hepatitis A complicated with progressive cholestasis and severe autoimmune hemolytic anemia. He was treated with high-dose prednisolone (1.5 mg/kg), and eventually recovered. His initial serum contained genotype IA hepatitis A virus (HAV), which was subsequently replaced by genotype IIIA HAV. Moreover, at the time of development of hemolytic anemia, he became positive for immunoglobulin M (IgM) anti-hepatitis E virus (HEV). We detected HAV antigens in the liver biopsy specimen, while we detected neither HEV antigen in the liver nor HEV RNA in his serum. This is the first report of hepatitis A coinfected with two different genotypes manifesting with autoimmune hemolytic anemia, prolonged cholestasis, and false-positive IgM anti-HEV.
Adult
;
Anemia, Hemolytic, Autoimmune/*diagnosis/drug therapy/etiology
;
Anti-Inflammatory Agents/therapeutic use
;
Cholestasis/*diagnosis/drug therapy/pathology
;
Coinfection/*diagnosis
;
Genotype
;
Hepatitis A/complications/*diagnosis/genetics
;
Hepatitis E/complications/*diagnosis/genetics
;
Humans
;
Immunoglobulin M/blood
;
Liver/pathology/virology
;
Male
;
Prednisolone/therapeutic use
;
RNA, Viral/blood
7.Superior Mesenteric Artery Syndrome Due to an Aortic Aneurysm in a Renal Transplant Recipient.
Hae Rim KIM ; Mahn Won PARK ; Seong Su LEE ; Mee Jung SHIN ; Joo Hyun PARK ; Chul Woo YANG ; Yong Soo KIM ; Yong Bok KOH ; In Sung MOON ; Byung Kee BANG
Journal of Korean Medical Science 2002;17(4):552-554
Superior mesenteric artery (SMA) syndrome is a rare disease in which the third portion of the duodenum is compressed by SMA. There are many causes leading to the SMA syndrome, however it's extremely rare that aortic aneurysm causes a SMA syndrome. We report a case of a successfully treated SMA syndrome due to an abdominal aortic aneurysm in a renal transplant recipient. The patient was a 52-yr-old woman with a thin stature (weight 40 kg, height 164 cm). She received a renal transplant 8 yr before, and had hypertension and abdominal aortic aneurysm. Her SMA syndrome developed in a prolonged supine position for the accidental rib fractures and was diagnosed by clinical and radiological findings. After a surgical correction (resection of an aneurysm and aortobiiliac bypass with an inverted Y graft), her symptoms relieved without deterioration of the graft function.
Aortic Aneurysm, Abdominal/*complications/surgery
;
Duodenal Obstruction
;
Duodenum/radiography
;
Female
;
Humans
;
*Kidney Transplantation
;
Middle Aged
;
Superior Mesenteric Artery Syndrome/*etiology/surgery
;
Tomography, X-Ray Computed
8.Comparative Analysis of Health Patterns and Gaps due to Environmental Influences in South Korea and North Korea, 2000–2017
Yoorim BANG ; Jongmin OH ; Eun Mee KIM ; Ji Hyen LEE ; Minah KANG ; Miju KIM ; Seok Hyang KIM ; Jae Jin HAN ; Hae Soon KIM ; Oran KWON ; Hunjoo HA ; Harris Hyun-soo KIM ; Hye Won CHUNG ; Eunshil KIM ; Young Ju KIM ; Yuri KIM ; Younhee KANG ; Eunhee HA
The Ewha Medical Journal 2022;45(4):e14-
Objectives:
To conduct a comparative study of children’s health in South Korea versus North Korea focusing on air pollution.
Methods:
We used annual mortality rate, prevalence, and environmental indicators data from the World Bank and World Health Organizations (WHO). Trend analysis of the two Koreas was conducted to evaluate changes in health status over time. Spearman’s correlation analysis was used to find out the correlation between environmental indicators and children’s health status.
Results:
We found a distinct gap in children’s health status between the two Koreas. While North Korea reported a higher death rate of children than South Korea, both showed a decreasing trend with the gap narrowing from 2000 to 2017. The prevalence of overweight and obesity increased and that of thinness decreased in both Koreas. Except PM2.5 exposure, South Korea reported higher figures in most indicators of air pollutant emissions (South Korea, mean (SD)=28.3 (2.0); North Korea, mean (SD)=36.5 (2.8), P-value=0.002).
Conclusion
This study empirically discovered the gaps and patterns of children’s health between South Korea and North Korea. North Korean children experienced more severe health outcomes than children in South Korea. These findings imply that epigenetic modification caused by environmental stressors affect children’s health in the two Koreas despite similar genetic characteristics. Considering the gaps in children’s health between the two Koreas, more attention and resources need to be directed towards North Korea because the necessary commodities and services to improve children’s health are lacking in North Korea.
9.The Treatment of Adult Acute Myelogenous Leukemia with AD Induction Therapy Followed by Consolidation Therapy with Intermediate Dose Ara-C; Long Term Follow-up Results.
Dae Ho LEE ; Soo Mee BANG ; Joo Young JUNG ; Jin Seok AHN ; Chul Won JUNG ; Kyung Hae JUNG ; Sung Soo YOON ; Myung Don OH ; Seonyang PARK ; Byoung Kook KIM ; Kang Won CHOE ; Han Ik CHO ; Noe Kyeong KIM
Korean Journal of Hematology 2002;37(2):97-105
BACKGROUND: This study was to evaluate the therapeutic efficacy of consolidation therapy based on intermediate dose Ara-C in patients with newly diagnosed acute myelogenous leukemia (AML) in Seoul National University Hospital. And also, this study was to assess the toxicities of the treatment. METHODS: We have reviewed retrospectively our experience of patients with newly diagnosed non-M3 AML between January 1993 and July 1997. They were treated with induction chemotherapy with Ara-C 200mg/m2/d over 24 h for 7 days and daunorubicin 45mg/m2/d daily for 3 days. The patients achieving complete remission (CR) are to receive the 3 courses of consolidation chemotherapy based on intermediate dose of Ara-C 1,000mg/m2 given over 2h every 12 h for a total of eight to ten doses. Patients having HLA-matched sibling donors with informed consent could receive allogeneic bone marrow transplantation (BMT). RESULTS: One hundred and fifteen patients were reviewed. The median age was 41 years (range, 16-69) and median follow-up was 75 months. The CR rate was 72.2%. The median disease-free survival (DFS) of patients receiving consolidation therapy and allogeneic BMT was 21 months and 26.5 months, respectively. The overall survival (OS) was 13 months for patients not-receiving consolidation therapy, 21 months for consolidation therapy, and 31 months for allogeneic BMT, respectively. The rate of treatment-related mortality of consolidation therapy was 14% and cause of all deaths was infection. But in allogeneic BMT, that mortality rate was 42%; 2 infections, 2 veno-occlusive diseases and 1 cyclophosphamide-induced cardiomyopathy. CONCLUSION: Patients receiving consolidation therapy with intermediate dose Ara-C had longer DFS and OS. But their DFS and OS was not superior to that of patients receiving allogeneic BMT. In addition, that result was inferior to that of patients receiving high dose Ara-C based consolidation therapy, compared with other previous studies. However, this study was retrospective and so further prospective study will be required for comparing different doses of Ara-C consolidation therapy versus BMT.
Adult*
;
Bone Marrow Transplantation
;
Cardiomyopathies
;
Consolidation Chemotherapy
;
Cytarabine*
;
Daunorubicin
;
Disease-Free Survival
;
Follow-Up Studies*
;
Humans
;
Induction Chemotherapy
;
Informed Consent
;
Leukemia, Myeloid, Acute*
;
Mortality
;
Retrospective Studies
;
Seoul
;
Siblings
;
Tissue Donors
10.Allogeneic Bone Marrow Transplantation for Acute Myelogenous Leukemia: Retrospective Analysis in a Single Institution.
Inho KIM ; Joo Young JUNG ; Soo Mee BANG ; Jae Ho BYUN ; Heung Moon CHANG ; Moon Hee LEE ; Young Jin YOO ; Jin Seok AHN ; Jong Tae LEE ; Seok Ah IM ; Chul Won JUNG ; Sung Hyun YANG ; Myung Don OH ; Kang Won CHOE ; Kyou Sup HAN ; Myoung Hee PARK ; Sung Whan HA ; Charn Il PARK ; Kyung Hae JUNG ; Seonyang PARK ; Byoung Kook KIM
Korean Journal of Hematology 1999;34(4):573-583
BACKGROUND: Acute myelogenous leukemia (AML) is the most common cause of leukemia in adults. Allogeneic bone marrow transplantation (BMT) for the treatment of AML is done worldwide now. METHODS: Between November 1987 and June 1998, we performed allogeneic BMT for 27 patients with AML from HLA-identical sibling donors. We reviewed medical records of these patients. RESULTS: The median age of patients was 31 (range, 15~43) and male to female ratio was 18 : 9. Conditioning regimens were BU/CY (busulfan, cyclophosphamide) for 22 patients, TBI/CY (total body irradiation, cyclophosphamide) for 3 patients, and TBI/VP/CY (TBI, VP-16, cyclophosphamide) for 2 patients. Cyclosporine and methotrexate were used in 18 patients for prophylaxis of graft-versus-host disease (GVHD), and cyclosporine and methyl-prednisolone were used in 9 patients. The median nucleated cell dose given to patients was 4.1x108 /kg. All evaluable patients achieved absolute neutrophil count of 500 /microliter after median 15 days after BMT (range, 11~45 days). Twenty-five percent of patients developed acute GVHD (> or = grade II) and there was no patient with grade IV acute GVHD. Twenty-nine percent developed chronic GVHD. Hepatic venoocclusive disease (VOD) occurred in 7 patients (26%). At the time of BMT, 16 patients were in the first remission status and 11 patients were in the advanced disease status. After a median follow-up of 27 months (range 7~127 months), the actuarial disease-free survival at 5 years was significantly higher in the first remission group than the others (44% vs. 9%; P=0.05). The difference of 5 year overall survival between these two groups approached statistical significance (50%for the first remission group and 12% for the others; P=0.13). There were 17 deaths. The causes of death were relapse (8 patients, 47%), VOD (3 patients, 18%), sepsis (2 patients, 12%), interstitial pneumonia (2 patients, 12%), chronic GVHD (1 patient, 6%), and drug-toxicity (1 patient, 6%). Eary deaths (<100 days) occurred in 6 patients (22%). CONCLUSION: Allogeneic BMT for patients with AML was most successful when done during the first remission. Clinical features of patients with AML treated with allogeneic BMT were similar to those from Western countries, but the incidence and severity of acute GVHD seem to be lower.
Adult
;
Bone Marrow Transplantation*
;
Bone Marrow*
;
Cause of Death
;
Cyclosporine
;
Disease-Free Survival
;
Etoposide
;
Female
;
Follow-Up Studies
;
Graft vs Host Disease
;
Humans
;
Incidence
;
Leukemia
;
Leukemia, Myeloid, Acute*
;
Lung Diseases, Interstitial
;
Male
;
Medical Records
;
Methotrexate
;
Neutrophils
;
Recurrence
;
Retrospective Studies*
;
Sepsis
;
Siblings
;
Tissue Donors